The trials were conducted at several centers in Japan and included patients with bilateral primary open-angle glaucoma or ocular
hypertension. After a 4-week period with latanoprost or carteolol
monotherapy, patients received 8 weeks of treatment with monotherapy,
concomitant therapy, or OPC-1085EL applied daily in the morning.
In study 1, the mean reduction in baseline-adjusted IOP for the 113 patients treated with OPC-1085EL (2.9 mm Hg) was significantly better
than for the 116 patients treated with latanoprost monotherapy (1.6 mm
Hg). In study 2, the mean reduction in baseline-adjusted IOP was
significantly better for OPC-1085EL (n = 76; 3.5 mm Hg) than for
carteolol (n = 76; 1.6 mm Hg). IOP reduction in the 37 patients who
received carteolol and latanoprost concomitantly was similar to that in
recipients of OPC-1085EL. In both studies, OPC-1085EL was tolerated
well and associated with only mild adverse drug reactions.
The authors concluded that OPC-1085EL is similar to concomitant therapy in terms of IOP-reducing efficacy but offers greater
convenience. They noted that subsequent studies are needed to evaluate
it for a longer duration, administered at other times of day, and in
more diverse populations.
